On the other hand, Finerenone exerts its cardiorenal protection at a different level, targeting MR overactivation, a major pro-inflammatory and pro-fibrotic driver of cardiorenal complications in T2D [135]. This evidence concerns the gene NR3C2 and type 2 diabetes mellitus.